Search company, investor...

Predict your next investment

Private Equity
merieux-developpement.com

Investments

28

Portfolio Exits

8

Funds

1

About Merieux Developpement

Merieux Developpement is an evergreen fund specialized in the healthcare sector, conducting growth and venture capital investments worldwide. Merieux Developpement works alongside entrepreneurs whose products and services can bring genuine advances to the health of patients and consumers, offering them access to its industry expertise and global network. Merieux Developpement is an affiliate of Institut Merieux, which employs around 13,000 employees worldwide with consolidated revenues exceeding EUR 2.0 billion in 2013. Other companies owned by Institut Merieux include bioMerieux (in vitro diagnostics), Merieux NutriSciences (food safety and nutrition services) and Transgene (immunotherapy).

Headquarters Location

17 Rue Bourgelat

Lyon, 69002,

France

+33 4 78 87 37 00

Want to inform investors similar to Merieux Developpement about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Merieux Developpement

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Merieux Developpement in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Merieux Developpement News

French medtech startup TISSIUM bags €50M

Jun 1, 2023

Paris-based TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, announced that it has closed €50M in a Series D round of funding. The financing comes from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation, and Sofinnova Partners. TISSIUM claims this latest round of funding comes at a time of significant milestones for the company, including its ongoing first-in-human study on its first nerve repair product — COAPTIUM Connect, in Australia and multiple ongoing regulatory activities. This funding will enable the French company to continue executing its development plan, supporting the commercialization of its initial nerve and hernia repair products. Furthermore, the capital will facilitate the expansion of its’s product pipeline and platform. TISSIUM intends to advance the development and commercialization of products derived from its unique biopolymer platform. According to the company, its products will address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction. At the core of TISSIUM’s technology platform lies a proprietary family of fully biosynthetic, biomorphic, and programmable polymers.

Merieux Developpement Investments

28 Investments

Merieux Developpement has made 28 investments. Their latest investment was in Keranova as part of their Series B on September 9, 2019.

CBI Logo

Merieux Developpement Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/10/2019

Series B

Keranova

$26.51M

No

1

5/28/2019

Seed

Waoup

$2.79M

Yes

1

4/4/2019

Series C - IV

Inscripta

$20M

No

5

12/19/2018

Series C - III

Subscribe to see more

$99M

Subscribe to see more

10

5/3/2018

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/10/2019

5/28/2019

4/4/2019

12/19/2018

5/3/2018

Round

Series B

Seed

Series C - IV

Series C - III

Private Equity

Company

Keranova

Waoup

Inscripta

Subscribe to see more

Subscribe to see more

Amount

$26.51M

$2.79M

$20M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

5

10

10

Merieux Developpement Portfolio Exits

8 Portfolio Exits

Merieux Developpement has 8 portfolio exits. Their latest portfolio exit was Ivantis on November 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/8/2021

Acquired

$99M

5

9/2/2021

Acq - Fin - IV

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/21/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/13/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/8/2021

9/2/2021

10/31/2018

6/21/2018

10/13/2017

Exit

Acquired

Acq - Fin - IV

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

10

10

Merieux Developpement Acquisitions

2 Acquisitions

Merieux Developpement acquired 2 companies. Their latest acquisition was STIPlastics on January 18, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/18/2018

$99M

Acq - Fin - II

2

3/21/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/18/2018

3/21/2016

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acq - Fin - II

Subscribe to see more

Sources

2

10

Merieux Developpement Fund History

1 Fund History

Merieux Developpement has 1 fund, including Merieux Developpement II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Merieux Developpement II

$188.35M

1

Closing Date

Fund

Merieux Developpement II

Fund Type

Status

Amount

$188.35M

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.